Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This 8-K Item 5.07 discloses the certified results of Alector's 2026 annual meeting of stockholders held on June 17, 2026, including voting outcomes for three proposals: election of Class II directors (Elizabeth Garofalo, Errol De Souza, and Kristine Yaffe), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (for, against, abstentions, broker non-votes) for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-17
Item 1.01
Outset Medical entered into a material amendment to its purchasing agreement with HCA on June 14, 2026, committing HCA to purchase approximately $40 million in new Tablo Hemodialysis Systems from 2026 through 2028, representing a significant multi-year commercial commitment affecting the company's revenue pipeline.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-17
Item 2.02
Item 2.02 disclosure explicitly references a press release issued on June 17, 2026, and states that textual information from that press release is being furnished in connection with "Results of Operations and Financial Condition." This is the standard format for earnings release disclosures under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
ImageneBio held its Annual Meeting on June 16, 2026, with shareholders voting on three proposals: election of two Class II directors (David P. Bonita and Joseph P. Slattery), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the 2025 Amended Equity Incentive Plan.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-17
Item 8.01
The Company entered into an underwriting agreement on June 15, 2026, to offer and sell 14,000,000 shares of common stock through a forward sale mechanism, with an additional 2,100,000 shares subject to an underwriter option. This is a material equity issuance that will dilute existing shareholders. Although structured as a forward sale (with settlement expected by June 16, 2027), the Company will receive net proceeds and contribute them to its operating partnership for acquisitions and general corporate purposes, making this a dilutive capital raise transaction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-06-17
Item 5.02
Stacey Moser was appointed as Chief Customer Officer, with the appointment announced on June 17, 2026 as part of organizational changes. The appointment is accompanied by a comprehensive compensation package including $500,000 in RSU equity awards and $500,000 in cash retention awards with specific vesting schedules and severance acceleration provisions.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 5.03
Allurion Technologies implemented a 1-for-15 reverse stock split, approved by stockholders at the December 2025 Annual Meeting, with the Charter Amendment filed on June 12, 2026 and effective June 17-18, 2026. This material corporate action affects the company's share structure, trading symbol, and terms of warrants and convertible securities.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
The Company resubmitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for Cushing's syndrome. This is a material regulatory milestone for a biopharmaceutical company, as NDA resubmission represents progress toward potential commercialization of a key product candidate. However, it does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M&A activity, or executive change), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 1.01
The Company entered into a Third Amended and Restated Operating Agreement on June 15, 2026, which amended the operating agreement to reflect the liquidation and dissolution of Series I and updated indemnification provisions. This represents a material structural change to the Company's organizational documents and governance framework.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-17
Item 1.01
Fiserv entered into an Underwriting Agreement on June 16, 2026, to issue €1 billion in senior notes (€500M due 2030 at 3.750% and €500M due 2034 at 4.250%) in a public offering expected to close June 23, 2026. While this is a debt issuance rather than a traditional M&A transaction, Item 1.01 ("Entry into a Material Definitive Agreement") captures material financing arrangements. The €1 billion aggregate principal amount and the formal underwriting structure with major investment banks (Citigroup, J.P. Morgan, TD, Wells Fargo) indicate materiality to investors assessing the company's capital structure and liquidity.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-17
Item 2.02
The filing discloses Odyssey Therapeutics' financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is the designated Item for disclosure of results of operations and financial condition.
View raw filing on EDGAR →
6-K
Financial Other
confidence 85%
filed 2026-06-17
The company completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash on June 17, 2026. This is a material asset sale generating substantial one-time cash proceeds. While it is a financial transaction, it does not fit the specific categories of debt issuance, dividend distribution, or dilutive issuance; it is best classified as a financial event (asset disposition) that does not fit a named category.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-17
Item 2.02
The filing discloses financial and operational results for the three months and year ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, reporting quarterly and annual financial results for a public company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-17
Item 1.01
Magnachip entered into an At Market Issuance Sales Agreement (ATM) on June 17, 2026, authorizing the sale of up to $50 million in common stock shares through B. Riley Securities. ATM offerings are classic dilutive equity issuances that signal capital raising and potential shareholder dilution. The material nature is confirmed by the $50 million aggregate offering price and the company's stated use of proceeds for strategic growth initiatives in AI data centers and robotics.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-17
Item 7.01
This disclosure announces the effective registration and imminent completion of a spin-off separation of Midera Food Processing, Inc. from The Middleby Corporation. The filing sets the record date (June 26, 2026) and expected distribution date (July 6, 2026) for a pro rata distribution of Midera shares to Middleby shareholders. This constitutes a material change of control and disposition event that fundamentally restructures the registrant's ownership and operations, fitting the ma_activity classification for a material separation/spin-off transaction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-17
Item 5.02
The filing's primary disclosure is the appointment of Matthew J. Koscal as a director and his concurrent assumption of the Chief Executive Officer role, effective June 15, 2026. While the section also addresses compensation updates and David Grizzle's transition from CEO to non-executive Chairman, the central event is Koscal's appointment to the Board and his succession to the CEO position, which is material to investors assessing leadership continuity and strategic direction.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-17
Item 5.02
The filing discloses a material compensatory arrangement: the Board approved a grant of 271,076 performance-based restricted stock units (PSUs) to CEO Dr. KR Sridhar on June 15, 2026, under the 2018 Equity Incentive Plan. The award is conditioned on objective revenue and margin targets through 2029 and includes a holding requirement through 2031, designed to retain the CEO and align his incentives with strategic growth priorities. This is a classic equity compensation disclosure under Item 5.02(e).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-17
Item 5.07
Acrivon held its Annual Meeting of Stockholders and disclosed voting results for three proposals: election of two Class I directors (Michael Tomsicek and Charles Baum), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the Amended and Restated 2022 Equity Incentive Plan. All three proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-17
Item 8.01
TTM Technologies announced entry into definitive stock purchase agreements to acquire two European companies—Swiss Technology Group AG and ILFA GmbH—in separate all-cash transactions subject to regulatory approval. The press release emphasizes these acquisitions as establishing TTM's initial European footprint and adding strategic PCB and materials capabilities across Medical, Aerospace & Defense markets. This is a material acquisition activity disclosed under Item 8.01 (Other Events) with expected close in Q3 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-17
Item 5.02
The company appointed Chris Hyder as Executive Vice President and Chief Operating Officer and Nina Barton as Executive Vice President and Chief Growth & Strategy Officer, both effective June 17, 2026. These material C-suite appointments include compensatory arrangements (salary increases and RSU grants) and reflect significant changes to the company's executive leadership structure.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-17
The 6-K discloses the results of an Annual Meeting of Shareholders held on June 16, 2026, with detailed voting tallies for eight proposals including director re-elections (Sam Moed, Yael Margolin, Adi Raviv), amendments to Articles of Association, CEO employment agreement amendment, equity grants to the CEO and Chairman, and auditor appointment. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the outcomes are material to investors as they confirm board composition, executive compensation arrangements, and auditor selection.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-17
EX-99.1
The press release announces that Wing Yip Food Holdings has regained compliance with Nasdaq Listing Rule 5550(a)(2) after previously falling below the US$1.00 minimum bid price requirement on December 22, 2025. This disclosure directly addresses a delisting risk — the company was non-compliant with a continued listing standard and faced potential delisting, but has now cured the deficiency. The resolution of a delisting-risk event is material to investors assessing the registrant's continued exchange listing status.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-06-17
EX-99.1
This announcement discloses the final results of a tender offer for VEON MidCo B.V.'s outstanding 3.375% Notes due 2027. The Company accepted U.S.$886,075,000 in principal amount of tendered notes for cash, reducing outstanding debt from U.S.$1,013,973,000 to U.S.$124,898,000. While technically a debt reduction rather than issuance, the tender offer represents a material modification of the Company's direct financial obligations and capital structure, warranting classification under debt-related activity. The materiality is evident from the scale of the transaction (approximately 87% of outstanding notes retired) and its impact on the registrant's leverage profile.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 85%
filed 2026-06-17
The Company entered into a convertible loan agreement with Cove Kaz Capital Group LLC on June 2, 2026, establishing a $45 million loan facility with $23.1 million already advanced. This creates a new direct financial obligation with specified interest terms (10% per annum). Although the instrument is convertible, the primary disclosure is the creation of the debt facility itself, which is a material capital event. The amendment to the concurrent merger transaction agreement clarifying cash-availability conditions reinforces the materiality of this financing arrangement.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-17
Item 7.01
The disclosure centers on the Company's regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule") after having been in violation as of December 19, 2025. While the news is positive (compliance restored), the core material event is the resolution of a delisting risk — the Company was previously at risk of delisting due to insufficient stockholders' equity and has now satisfied Nasdaq's requirements, subject to maintaining $5 million in equity for twelve months. This directly addresses a continued listing qualification matter under Item 3.01 principles, making it a delisting_risk classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-17
Item 7.01
The filing discloses that Silicon Valley Acquisition Corp. (SVAQ) and EigenQ Inc. have entered into a definitive business combination agreement pursuant to which SVAQ and EigenQ would combine and EigenQ would become a public company. This is a material acquisition/merger transaction requiring shareholder approval and SEC registration, clearly falling under Item 1.01 (Material Agreements) and Item 2.01 (Completion of Acquisition or Disposal of Assets) territory, even though disclosed under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
6-K
Governance Other
confidence 70%
filed 2026-06-17
EX-99.1
Wellchange Holdings announced three consecutive shareholder meetings scheduled for July 6, 2026 (Class A Meeting, Class B Meeting, and Annual General Meeting) to vote on material governance changes including an increase in Class B voting rights from 35 to 100 votes per share, a 1-for-400 Class A share consolidation, a par value reduction, share capital increase, and amendments to the memorandum and articles of association.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-17
EX-99.1
AIFU announced it has signed a non-binding Memorandum of Understanding to acquire Peakleap Ventures Limited, a company specializing in industrial AI solutions. The press release explicitly states this represents a "strategic transformation" and would transform the company "from a single-finance digital platform into a dual-engine ecosystem powered by 'Industrial AI + Digital Finance.'" This is a material acquisition announcement that would significantly affect investor assessment of the company's strategic direction and business composition.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-17
EX-99.1
The press release announces a 1-for-3 reverse stock split explicitly undertaken to "regain compliance with Nasdaq's Minimum Bid Price Requirement and Protecting Continued Listing Status." The company states it fell below the $1.00 minimum bid price threshold and faces potential delisting under Nasdaq Listing Rule 5810(c)(3)(A) if it does not comply. This is a material disclosure of delisting risk and the remedial action taken to address it.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-17
EX-99.1
The press release announces entry into a "material definitive agreement" whereby Linkers Industries Limited, through its subsidiary Linkers Asia Pacific Limited, agreed to purchase 29% of LPW Electronics Co., Ltd. for approximately US$2.35 million plus assumption of US$6.16 million in liabilities, increasing the Company's ownership from 20% to 49%. This is a material acquisition activity that would materially affect investor assessment of the registrant's strategic position and capital deployment.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 5.03
Lakewood-Amedex Biotherapeutics approved and implemented a 1-for-10 reverse stock split, effective June 19, 2026, which was filed with the Nevada Secretary of State. This structural capital event materially modifies the rights of security holders by reducing share count and affecting trading mechanics and investor holdings.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting held on June 16, 2026, filed under Item 5.07. The filing reports voting outcomes on four matters: election of three Class A directors (Rod Baltzer, Renee Hornbaker, Christa Steele), ratification of CBIZ CPAs as independent auditor, advisory vote on executive compensation, and advisory vote on frequency of future compensation votes. All proposals passed with disclosed vote tallies and quorum information (60.13% attendance).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
Stockholders approved three proposals at the Annual Meeting held on June 16, 2026: election of five directors (David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda, and Marcia Allen), ratification of CBIZ CPAs P.C. as independent auditors, and approval of the Third Amended and Restated 2021 Stock Incentive Plan with increased reserved shares and an evergreen provision.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-17
EX-99.1
This press release announces receipt of an additional order for ParaZero's DefendAir Net Pod system from a second business unit of a Tier-1 Israeli defense company, including engineering integration support. While the disclosure is clearly operational and business-related (a customer order for the company's Counter-UAS product), it does not fit the specific `earnings_release` category (no financial results disclosed) nor any other named event type. The order represents a material commercial development that would affect a reasonable investor's assessment of the company's market traction and revenue pipeline, warranting classification as `operational_other`.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-17
Item 1.01
The Company entered into a Securities Purchase Agreement to issue 15,000,000 shares of common stock for $3,750,000 in proceeds to three investors. This is a private placement of unregistered equity securities, which is a classic dilutive issuance event. The substantial share count and capital raise would materially affect a reasonable investor's assessment of ownership dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 2.03
ISQ Open Infrastructure entered into a $60 million revolving credit facility (expandable to $180 million) on June 11, 2026, creating a direct financial obligation with customary covenants and events of default.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
Faraday Future announced a major product launch on June 16, 2026, including unveiling its "full-form EAI Robot World spanning six product series," launching a "Three-in-One EAI robotics education ecosystem strategy," and debuting an "All-New Futurist humanoid robot and FX Navi with pricing starting at $1,990." This represents a significant business development and product diversification announcement that would materially affect investor assessment of the company's strategic direction and revenue prospects, but does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or other defined event type).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-17
Item 8.01
The filing discloses a material business combination agreement entered into on February 22, 2026, between RAAQ and IQM Quantum Computers Oy that will result in IQM becoming a publicly traded company. The June 17, 2026 8-K Item 8.01 announces the effectiveness of the Registration Statement (June 5, 2026) and the mailing of the definitive proxy statement/prospectus to shareholders for an upcoming Extraordinary General Meeting to vote on the Transaction. This is a material acquisition/change of control event that would substantially affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-17
Item 2.01
This disclosure reports the completion of a disposition of a 100% equity interest in Bless HK (indirect owner of Jingshan subsidiary) to an unaffiliated third party on June 15, 2026. Although the consideration was nominal and the subsidiary was non-operating, the transaction constitutes a material change of control and elimination of a consolidated subsidiary from the Company's financial statements, which would affect a reasonable investor's assessment of the registrant's asset base and strategic direction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-17
JAB Acquisition Corp I disclosed the consummation of its initial public offering on June 11, 2026, raising $172.5 million in gross proceeds from 17.25 million units, plus a concurrent private placement of 260,000 units for $2.6 million. While technically an IPO/capital raise rather than a traditional M&A transaction, this represents a material capital event that establishes the company's public shell structure for a future business combination. The filing is disclosed under Item 8.01 (Other Events) and includes detailed terms of the securities issued, making it a material event affecting the registrant's capitalization and structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-17
Item 3.02
Collective Acquisition Corp. II completed unregistered sales of equity securities, including exercise of an over-allotment option generating $33 million in additional proceeds and a related private placement of $330 thousand, as part of the SPAC's IPO capitalization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-17
EX-99.1
This press release announces Yueda Digital Holding's "Solon Initiative," a strategic product launch targeting enterprise governance infrastructure for AI-agent-originated on-chain payments. The disclosure describes a new business initiative, architectural design principles, and market positioning rather than a discrete financial event (earnings, debt, M&A) or governance action (executive change, shareholder vote). As a material strategic initiative that defines the company's product direction and competitive positioning in an emerging market segment, it qualifies as an operational/strategic business event without a more specific category fit.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-17
The filing discloses results of T1 Energy Inc.'s annual meeting of stockholders held on June 17, 2026, under Item 5.07. Four proposals were submitted to a vote: election of eight directors, ratification of KPMG LLP as independent auditor, advisory vote on named executive officer compensation, and approval of an amendment to increase authorized common shares from 500 million to 1 billion. All proposals passed with substantial majorities. This is a material disclosure of shareholder voting outcomes that affects investor understanding of corporate governance and capital structure.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-17
EX-99.1
This disclosure announces that Holcim Ltd., which acquired a controlling interest in Cementos Pacasmayo (disclosed in prior material events on March 30 and May 14, 2026), has requested an exemption from the SMV to conduct a subsequent Tender Offer (OPA) for up to 100% of the remaining shares not owned by its subsidiary Inversiones ASPI S.A. This is a material acquisition-related activity — the completion phase of a change of control through a mandatory tender offer, which directly affects minority shareholders' rights and the company's ownership structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-17
Item 1.01
HEICO entered into a fourth amendment to its revolving credit facility on June 11, 2026, which increased capacity from $2.0 billion to $2.2 billion, extended maturity to June 11, 2031, and modified rating-based pricing terms. While this is a material refinancing and credit facility modification that affects the company's financial flexibility and debt structure, it is not a traditional M&A transaction. However, Item 1.01 is being used here, which typically covers material definitive agreements including significant credit facility amendments. The materiality is clear given the $200 million capacity increase and five-year maturity extension, but the event is more accurately characterized as a material credit facility amendment rather than M&A activity proper.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-17
The 6-K discloses a Nasdaq deficiency notice dated June 11, 2026, informing Scage Future that its ADSs failed to maintain the minimum $1.00 bid price required by Nasdaq Listing Rule 5550(a)(2). The Company has until December 8, 2026 to regain compliance or faces potential delisting. This is a material delisting risk disclosure that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-06-17
The filing discloses results of a shareholder meeting held on June 16, 2026, where two proposals were voted on: (1) the Extension Amendment Proposal to extend the Business Combination Period through December 20, 2026, approved with 15,687,094 votes for and 3,284,050 against, and (2) the Auditor Ratification Proposal, approved with 16,788,360 votes for and 3,458,663 against. Item 5.07 explicitly reports submission of matters to a vote of security holders with detailed voting results, which is the defining characteristic of shareholder_vote_results. The extension of the combination period is material to investors in a SPAC, as it directly affects the timeline for completing a business combination.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-17
Item 5.07
This Item 5.07 discloses the results of Fly-E Group's 2025 Annual Meeting of Shareholders held on June 17, 2026, including voting outcomes on three proposals: election of four directors (all approved with overwhelming support), ratification of Fortune CPA, Inc. as independent auditor (approved), and authorization for a reverse stock split at a 1-for-5 to 1-for-100 ratio at the Board's discretion (approved). The reverse stock split authorization is material to investors as it signals potential delisting risk mitigation or capital structure restructuring.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 8.01
This Item 8.01 discloses the completion and post-closing mechanics of an IPO (20 million units at $10/unit generating $200M gross proceeds), a concurrent private placement ($2.1M), partial exercise of an over-allotment option (1.65M units, $16.5M), and placement of $216.5M in trust. While IPO completion is material, the disclosure is primarily administrative detail about capital raised and trust account mechanics rather than a discrete earnings release, M&A event, or other specific taxonomy event. The filing reports "as previously reported" events, suggesting this is a follow-up disclosure of already-announced transactions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-17
The filing discloses completion of a material acquisition on June 17, 2026, whereby Rumble Inc. acquired approximately 85.2% of Northern Data AG through an exchange offer and direct purchases from transaction support agreement sellers. Item 2.01 explicitly states "Completion of Acquisition or Disposition of Assets" and describes the issuance of 16.6 million shares to public shareholders and 42.8 million shares plus pre-funded warrants to TSA Sellers as consideration. This is a transformative business combination involving a substantial equity issuance and acquisition of a controlling stake in a foreign corporation.
View raw filing on EDGAR →